September 5, 2014 / 2:53 PM / 3 years ago

BUZZ-IntelliPharmaceuticals International: Research action

1 Min Read

** Canadian drugmaker's U.S.-listed shares up 16 pct at $3.15

** Maxim Group analysts upgrade stock to "buy" and raised price target to $7 from $3

** "Based on our estimates of the numerous phase I trials now underway, we believe we could see Rexista (pain-killer drug) expedited in the marketplace much faster than we previously expected," analyst wrote in a note

** Up to Thursday's close, stock has fallen 27 percent this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below